Skip to content
value.today

Carlsmed, Inc.

CARL
$420 Mmarket cap on Oct 29, 2026
Compare
World rank
#13,346
Revenue
$51 M
For year ending December-2025
Net income
$-30 M
-58.7% margin
SEC filing
Employees
—

Carlsmed, Inc. in brief

Carlsmed, Inc. is a listed company in the Healthcare sector, based in Carlsbad, California, USA. Its market value was $420 M on 29 October 2026, which makes it the 13,346th largest listed company in the world and the 2,645th largest in the USA on this site. In the year to December 2025 it had sales of $51 M and a net loss of $30 M. Michael Cordonnier is its chief executive. Its shares trade under the symbol CARL (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Carlsmed, Inc.

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a focus on becoming the standard of care for spine fusion surgery. Our mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. The aprevo Technology Platform was designed to address the limitations of traditional lumbar and cervical spine fusion surgery, aiming to optimize patient outcomes and reduce the need for revision surgeries.

Our technology is powered by AI-enabled, outcome-based algorithms that provide personalized surgical plans for spine fusion. The aprevo surgical kit delivered to customers includes interbody implants for a custom vertebral fit for each patient’s unique pathology and bone topography, and single-use surgical instruments. The aprevo Technology Platform supports surgeons in achieving proper spinal alignment for patients with degenerative disc disease, which can improve clinical outcomes and reduce the likelihood of revision surgeries. We currently market the aprevo Technology Platform for lumbar and cervical spine fusion surgeries.

From the company's annual report filed with the US SEC: read the report

Carlsmed, Inc. timeline

2 events, 2019–2025
  1. 2019
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2025
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 24 July 2025; shares registered for exchange trading on 21 July 2025.

Events of Carlsmed, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$113 M$227 M$340 M$453 M

World rank over time

▼ down 150 places since 2026
2026-08-01: #13224#13,22420262026-10-14: #13663#13,66320262026-10-29: #13374#13,3742026

Rank in USA: #2,684 (Aug 2026) · #2,666 (Oct 2026) · #2,648 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
5.8×
Price / book
4.2×
Free cash flow yield
-7.1%
Net margin (TTM)
-55.8%
Operating margin
-60.5%
Return on equity
-40.5%
Liabilities / assets
24.0%
Net debt
$-70M
Revenue growth
+86.0%
R&D / revenue
33.7%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2024: revenue $27M, net income $-24M$27MFY24Fiscal year ending Dec 2025: revenue $51M, net income $-30M$51MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$51M+86.0%$-31M$-30M-58.7%
Dec 2024$27M—$-24M$-24M-89.3%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-29M$1M$-30M$-2.12—
Dec 2024$-25M$0M$-26M$-6.11—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$72M
Net income, trailing 12 months
$-40M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-5M—Dec ’24Three months to Mar 2025: revenue $10M, net income $-6M$10MMar ’25Three months to Jun 2025: revenue $12M, net income $-7M$12MJun ’25Three months to Sep 2025: revenue $13M, net income $-9M$13MSep ’25Three months to Dec 2025 (from the annual report): revenue $15M, net income $-9M$15MDec ’25Three months to Mar 2026: revenue $16M, net income $-9M$16MMar ’26Three months to Jun 2026: revenue $19M, net income $-11M$19MJun ’26Three months to Sep 2026: revenue $22M, net income $-12M$22MSep ’26

Latest quarter to Sep 2026: revenue $22M (+64.9% on a year earlier), net income $-12M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Carlsmed, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$51 M
Operating income
$-31 M
Net income
$-30 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$130 M
Total liabilities
$31 M
Total equity
$99 M

As of December-2025

Top 87 institutional investors in Carlsmed, Inc.#

As of Sep 30, 2026
87 institutions held 6.3 M shares (about 23.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 16.9%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Carlsmed, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Parkman Healthcare Partners LLC779,757+182,439 (+30.54%)2.85%$11 MNov 16, 2026
2Janus Henderson Group Ltd.726,196—2.65%$10 MNov 16, 2026
3BlackRock, Inc.581,660+49,067 (+9.21%)2.12%$8 MNov 13, 2026
4Pier Capital, LLC518,711+145,034 (+38.81%)1.89%$7 MNov 13, 2026
5Cadian Capital Management, LP500,096New1.82%$7 MNov 16, 2026
6Point72 Asset Management, L.P.495,820New1.81%$7 MNov 16, 2026
7Vanguard Capital Management LLC281,407+42,680 (+17.88%)1.03%$4 MNov 13, 2026
8Palumbo Wealth Management LLC265,891-1,407 (-0.53%)0.97%$4 MNov 13, 2026
9Russell Investments Group, Ltd.257,805+118,663 (+85.28%)0.94%$4 MNov 6, 2026
10Geode Capital Management, LLC234,901+30,246 (+14.78%)0.86%$3 MNov 6, 2026
11D. E. Shaw & Co., Inc.150,842+90,403 (+149.58%)0.55%$2 MNov 16, 2026
12State Street Corp138,144+5,061 (+3.80%)0.50%$2 MNov 12, 2026
13AQR Capital Management LLC86,657-5,502 (-5.97%)0.32%$1 MNov 16, 2026
14Schonfeld Strategic Advisors LLC80,089-144,715 (-64.37%)0.29%$1 MNov 16, 2026
15Tocqueville Asset Management L.P.80,000New0.29%$1 MNov 13, 2026
16Citadel Advisors LLC67,706-34,020 (-33.44%)0.25%$1 MNov 16, 2026
17Northern Trust Corp67,659+3,026 (+4.68%)0.25%$1 MNov 16, 2026
18Vanguard Fiduciary Trust Co65,860+15,932 (+31.91%)0.24%$1 MNov 13, 2026
19BNP Paribas Financial Markets62,570+22,619 (+56.62%)0.23%$1 MNov 12, 2026
20Millennium Management LLC60,617-235,290 (-79.51%)0.22%$1 MNov 16, 2026
21Vanguard Portfolio Management LLC57,983+1,035 (+1.82%)0.21%$1 MNov 13, 2026
22Goldman Sachs Group Inc52,592-10,534 (-16.69%)0.19%$1 MNov 16, 2026
23Kornitzer Capital Management Inc /KS49,769-1,919 (-3.71%)0.18%$1 MNov 3, 2026
24Two Sigma Investments, LP48,107+30,099 (+167.14%)0.18%$1 MNov 16, 2026
25Boston Partners43,923+21,548 (+96.30%)0.16%$1 MNov 10, 2026
Show all 87: investors 26 to 87
Institutional investors 26 to 87 in Carlsmed, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Trexquant Investment LP40,655+29,654 (+269.56%)0.15%$1 MNov 16, 2026
27Morgan Stanley38,427+7,728 (+25.17%)0.14%$1 MNov 13, 2026
28Bridgeway Capital Management, LLC32,006+7,006 (+28.02%)0.12%$0 MNov 16, 2026
29Empowered Funds, LLC32,006New0.12%$0 MNov 13, 2026
30XTX Topco Ltd31,132New0.11%$0 MNov 16, 2026
31Walleye Capital LLC27,787New0.10%$0 MNov 13, 2026
32Jump Financial, LLC26,400+6,986 (+35.98%)0.10%$0 MNov 13, 2026
33Jane Street Group, LLC26,370-47,019 (-64.07%)0.10%$0 MNov 12, 2026
34Charles Schwab Investment Management Inc20,426+3,150 (+18.23%)0.07%$0 MNov 16, 2026
35Prudential Financial Inc19,618New0.07%$0 MNov 16, 2026
36Bank of New York Mellon Corp19,024+1,572 (+9.01%)0.07%$0 MNov 5, 2026
37Jpmorgan Chase & Co18,162+12,898 (+245.02%)0.07%$0 MNov 12, 2026
38Zevenbergen Capital Investments LLC17,900+6,000 (+50.42%)0.07%$0 MOct 8, 2026
39Occudo Quantitative Strategies LP17,586New0.06%$0 MNov 16, 2026
40Mercer Global Advisors Inc /adv17,057-405 (-2.32%)0.06%$0 MNov 16, 2026
41Alpine Woods Capital Investors, LLC16,044+502 (+3.23%)0.06%$0 MNov 13, 2026
42Bank Of America Corp /de/15,512+5,116 (+49.21%)0.06%$0 MNov 16, 2026
43Centiva Capital, LP14,716-175 (-1.18%)0.05%$0 MNov 13, 2026
44Janney Montgomery Scott LLC14,025+1,000 (+7.68%)0.05%$0 MNov 12, 2026
45Board of Trustees of The Leland Stanford Junior University12,5160 (0.00%)0.05%$0 MNov 16, 2026
46UBS Group AG12,168-4,581 (-27.35%)0.04%$0 MNov 10, 2026
47Quadrature Capital Ltd12,113New0.04%$0 MNov 13, 2026
48Entropy Technologies, LP11,345New0.04%$0 MNov 13, 2026
49Gsa Capital Partners LLP11,249New0.04%$0 MNov 16, 2026
50Nuveen, LLC9,932New0.04%$0 MNov 10, 2026
51Rhumbline Advisers9,921+4,133 (+71.41%)0.04%$0 MNov 10, 2026
52Deutsche Bank AG\7,119-3,061 (-30.07%)0.03%$0 MNov 6, 2026
53Citigroup Inc4,474+97 (+2.22%)0.02%$0 MNov 4, 2026
54MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.4,043+150 (+3.85%)0.01%$0 MNov 16, 2026
55Vanguard Global Advisers, LLC3,626+49 (+1.37%)0.01%$0 MNov 13, 2026
56Barclays PLC3,298+1,855 (+128.55%)0.01%$0 MNov 6, 2026
57Wells Fargo & Company/mn2,424-5,299 (-68.61%)0.01%$0 MNov 16, 2026
58New York State Common Retirement Fund1,8000 (0.00%)0.01%$0 MNov 17, 2026
59Police & Firemen's Retirement System of New Jersey1,2580 (0.00%)0.00%$0 MNov 9, 2026
60Armstrong Advisory Group, Inc1,2340 (0.00%)0.00%$0 MOct 9, 2026
61FMR LLC1,165+10 (+0.87%)0.00%$0 MNov 10, 2026
62Arax Advisory Partners939+190 (+25.37%)0.00%$0 MNov 12, 2026
63Tower Research Capital LLC (TRC)833-372 (-30.87%)0.00%$0 MNov 16, 2026
64Quarry LP737New0.00%$0 MNov 16, 2026
65Legal & General Group Plc685-339 (-33.11%)0.00%$0 MNov 16, 2026
66Ameritas Investment Partners, Inc.5650 (0.00%)0.00%$0 MNov 13, 2026
67Jones Financial Companies Lllp530-100 (-15.87%)0.00%$0 MNov 13, 2026
68Royal Bank Of Canada442-58 (-11.60%)0.00%$0 MNov 16, 2026
69Farther Finance Advisors, LLC261+165 (+171.88%)0.00%$0 MOct 8, 2026
70Sterling Capital Management LLC217+112 (+106.67%)0.00%$0 MOct 22, 2026
71Steward Partners Investment Advisory, LLC217New0.00%$0 MNov 13, 2026
72Allworth Financial LP203+23 (+12.78%)0.00%$0 MNov 17, 2026
73EverSource Wealth Advisors, LLC145-62 (-29.95%)0.00%$0 MNov 4, 2026
74Osaic Holdings, Inc.120+100 (+500.00%)0.00%$0 MNov 12, 2026
75California State Teachers Retirement System1140 (0.00%)0.00%$0 MNov 13, 2026
76Physician Wealth Advisors, Inc.91New0.00%$0 MOct 20, 2026
77Root Financial Partners, LLC85New0.00%$0 MOct 21, 2026
78Essential Partners LLC67-1 (-1.47%)0.00%$0 MOct 14, 2026
79SJS Investment Consulting Inc.54+35 (+184.21%)0.00%$0 MOct 26, 2026
80IFP Advisors, Inc52-1 (-1.89%)0.00%$0 MOct 16, 2026
81True Wealth Design, LLC47-5 (-9.62%)0.00%$0 MOct 13, 2026
82Fortitude Family Office, LLC41+11 (+36.67%)0.00%$0 MOct 14, 2026
83Rothschild Investment LLC240 (0.00%)0.00%$0 MNov 10, 2026
84GAMMA Investing LLC12New0.00%$0 MOct 8, 2026
85Caitong International Asset Management Co., Ltd11+4 (+57.14%)0.00%$0 MOct 29, 2026
86Clearstead Advisors, LLC1-4 (-80.00%)0.00%$0 MNov 6, 2026
87JPL Wealth Management, LLC10 (0.00%)0.00%$0 MNov 13, 2026

Mutual funds holding Carlsmed, Inc.#

65 funds in 2 countries hold shares worth $23 M (about 7.9% of the company). Since their previous reports 30 added shares and 10 sold, buying $4 M net. By country: USA 64 ($22 M), Sweden 1 ($1 M).
Mutual funds holding Carlsmed, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Janus Henderson Venture FundJanus Investment Fund609,059$6 M2.2%0.17%+3.6%Jun 30, 2026
🇺🇸 Janus Henderson Small Cap Value FundJanus Henderson Investors US LLC343,579$4 M1.3%0.28%no changeJun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors213,041$2 M0.78%<0.01%+23%Jun 30, 2026
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.158,583$2 M0.58%<0.01%−19%Jun 30, 2026
🇸🇪 SEB Nordamerikafond SmåbolagSEB Funds AB130,204$1 M0.48%0.48%newJun 30, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC102,893$1 M0.38%0.13%+105%Jul 31, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC93,117$1 M0.34%<0.01%+14%Jul 31, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.73,487$1 M0.27%<0.01%−0.4%Jun 30, 2026
🇺🇸 Adara Smaller Companies FundRBB Fund, Inc.59,725$1 M0.22%0.08%newMay 31, 2026
🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc.41,408$0 M0.15%<0.01%+23%May 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors44,451$0 M0.16%<0.01%+1.0%Jun 30, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors41,737$0 M0.15%<0.01%+126%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC36,140$0 M0.13%<0.01%+3.5%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors28,345$0 M0.10%0.02%+40%Jun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC25,000$0 M0.09%0.18%newJun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.20,399$0 M0.07%<0.01%+22%Jul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC16,880$0 M0.06%<0.01%+6.6%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC12,014$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 U.S. Small Cap Equity FundRussell Investment Management, LLC12,922$0 M0.05%0.05%no changeJun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC11,392$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC10,100$0 M0.04%<0.01%+7.8%May 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC8,160$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation6,700$0 M0.02%<0.01%+347%Jun 30, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC6,428$0 M0.02%<0.01%+93%Jun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC5,976$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc.4,974$0 M0.02%<0.01%+16%May 31, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC4,034$0 M0.01%<0.01%+33%Jul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.4,439$0 M0.02%<0.01%−8.8%Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.3,774$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC3,736$0 M0.01%<0.01%−10%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC3,600$0 M0.01%<0.01%+225%Jun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.3,500$0 M0.01%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.2,883$0 M0.01%<0.01%−27%Jun 30, 2026
🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company2,603$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc.2,166$0 M<0.01%<0.01%+36%May 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC1,915$0 M<0.01%<0.01%+32%Jun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC1,452$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.1,062$0 M<0.01%<0.01%+3.2%Jul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC1,203$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC1,200$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC1,200$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS1,178$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.1,014$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC616$0 M<0.01%<0.01%+6.0%Jul 31, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC720$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC578$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Bridge Builder Small/Mid Cap Growth FundOLIVE STREET INVESTMENT ADVISERS LLC687$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.669$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc.557$0 M<0.01%<0.01%no changeMay 31, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC613$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC582$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC473$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS474$0 M<0.01%<0.01%no changeJul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management565$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC559$0 M<0.01%<0.01%+6.5%Jun 30, 2026
🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC381$0 M<0.01%<0.01%+30%May 31, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC413$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC342$0 M<0.01%<0.01%+143%Jul 31, 2026
🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC306$0 M<0.01%<0.01%−26%May 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC336$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC299$0 M<0.01%<0.01%−29%May 31, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC306$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.234$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC193$0 M<0.01%<0.01%newMay 31, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC152$0 M<0.01%<0.01%no changeJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 65 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Carlsmed, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$2.7 M
5 sales, 2 insiders
Net, 12 months
-$2.7 M
open market only
Insiders on file
14
since
$28.1 M-$2.6 M$0Jul 2025: bought $28.1 M (6 trades), sold $0 (0 trades)Jul 25Mar 2026: bought $0 (0 trades), sold $2.6 M (1 trades)MarSep 2026: bought $0 (0 trades), sold $3 K (1 trades)SepOct 2026: bought $0 (0 trades), sold $15 K (2 trades)OctNov 2026: bought $0 (0 trades), sold $11 K (1 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Carlsmed, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Jeffrey BertoliniChief Operating OfficerOption exercise10b5-1 plan+747$5.915$4 K23,236Form 4
filed Jeffrey BertoliniChief Operating OfficerSell10b5-1 plan-747$15.15$11 K22,489Form 4
filed Jeffrey BertoliniChief Operating OfficerOption exercise10b5-1 plan+243$2.232$54222,732Form 4
filed Jeffrey BertoliniChief Operating OfficerSell10b5-1 plan-243$15.80$4 K22,489Form 4
filed Jeffrey BertoliniChief Operating OfficerOption exercise10b5-1 plan+747$5.915$4 K23,236Form 4
filed Jeffrey BertoliniChief Operating OfficerSell10b5-1 plan-747$14.39$11 K22,489Form 4
filed Jeffrey BertoliniChief Operating OfficerOption exercise10b5-1 plan+243$2.232$54222,732Form 4
filed Jeffrey BertoliniChief Operating OfficerSell10b5-1 plan-243$13.99$3 K22,489Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Carlsmed, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
1.2 M
4.7% of shares · 15.07 days to cover
Shares sold short, last 24 reportsAll stocks →

IPO: priced at $15.00, raising $100.5M · IPO calendar

Stock splits: 1-for-5.59 reverse split

Fails to deliver

  • : 12 shares at $15.31
  • : 115 shares at $15.42
  • : 528 shares at $14.47
  • : 180 shares at $14.78
  • : 2 shares at $14.05

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Carlsmed, Inc. scorecard#

Passes 5 of the 16 checks that could be worked out: strongest in financial health (4 of 5), weakest in valuation (0 of 5). Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation0 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median4.2×Price to book 4.2× against Healthcare's median of 3.1×.
    • ✗Price to sales below its peers' median5.8×Price to sales 5.8× against Healthcare's median of 3.8×.
    • ✗Free cash flow yield above 5%-7.1%Free cash flow is -7.1% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • ✓Revenue grew in the newest year86.0%Revenue up 86.0% in fiscal 2025.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-2.12 vs -6.11Diluted EPS -2.12 in fiscal 2025 against -6.11 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$30 MNet income -$30 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • ✗Operating margin above its peers' median-60.5%-60.5% against Healthcare's median of -7.7% (674 companies).
    • ✗Return on equity above 15%-209.8%-209.8% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health4 of 5
    • ✓Short-term assets cover short-term liabilities8.9×Current ratio 8.87 at the end of fiscal 2025.
    • ✓Debt below equity0.2×Debt to equity 0.16 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $70 M at the end of fiscal 2025.
    • ✗Operating income covers interest five times-21.4×Operating income -21.4 times interest in fiscal 2025.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • ✓Altman Z-score outside the distress zone7.62Z-score 7.62 (safe zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year249.8%Diluted shares up 249.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Healthcare, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Carlsmed, Inc.'s statements, beside the median of Healthcare.

Carlsmed, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-60.5%-7.7%
Net margin-58.7%-8.1%
Return on equity-209.8%-36.9%
Revenue growth86.0%10.2%
Debt to equity0.16×0.45×
Free cash flow margin-58.6%-1.3%

5of 9on the Piotroski tests of financial strength

  • Net loss of $30 million.
  • Free cash flow was negative: -$30 million.
  • The share count rose 249.8% in the year.
  • Operating income covers the interest bill only -21.4 times.

Carlsmed, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Carlsmed, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024
Income statement
Revenue5127
Cost of revenue127.1
Gross profit3820
Research and development1714
Selling and marketing3521
General and administrative178.4
Operating expenses6944
Operating income−31−24
Interest and finance income2.71.3
Interest expense and finance costs1.41.3
Other non-operating income (expense)0.9−0.1
Income tax00
Net income attributable to shareholders−30−24
Earnings per share, basic-2.12-6.11
Earnings per share, diluted-2.12-6.11
Shares, weighted average (basic)144.1
Shares, weighted average (diluted)144.1
Balance sheet
Cash and cash equivalents8640
Short-term investments240
Receivables116.8
Inventory1.81.0
Other current assets3.61.4
Current assets12749
Property, plant and equipment1.50.3
Right-of-use (leased) assets1.81.6
Total assets13052
Accounts payable4.52.4
Current liabilities148.8
Lease liabilities (non-current)1.31.3
Total liabilities3126
Retained earnings−101−71
Shareholders' equity99−71
Total liabilities and equity13052
Shares outstanding274.1
Cash-flow statement
Depreciation and amortization0.30.1
Share-based compensation1.90.3
Cash from operating activities−29−25
Capital expenditure−0.6−0.2
Cash from investing activities−25−0.2
Cash from financing activities10058
Report10-K10-K

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at Carlsmed, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 2 · Material agreement 1 · New debt 1 · Bylaws or fiscal year changed 1 · Shareholder vote 1 · Results announced 7

Carlsmed, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Results announced8-K
Material agreementNew debt8-K
Results announced8-K
Bylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

3 private funding rounds before listing

Private share sales · funding history

Private share sales of Carlsmed, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2024$65 MNo. 3$50 to $250 million7equitySEC
Apr 2022$30 MNo. 2$10 to $50 million21equitySEC
Dec 2020$13 MNo. 1$10 to $50 million50equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Carlsmed, Inc.#

$80 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues and medicare/medicaid.

Lobbying, 2025
$80 K
#1,298 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$140 K
  • Health Issues4 reports
  • Medicare/Medicaid4 reports

Lobbying firms hired in 2025

Manatt, Phelps, and Phillips $80 K

Carlsmed, Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$140 K—3
2025$80 K—4
2024$220 K—6

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Carlsmed Inc” and “Carlsmed, Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

How Carlsmed, Inc. compares in Healthcare

  • Market cap$420 M · higher than 43% of 2,013
  • Revenue$51 M · higher than 34% of 1,795
  • Net margin-55.8% · higher than 22% of 1,485
  • Revenue growth86.0% · higher than 88% of 1,003
  • Price / sales5.8× · lower than 35% of 1,071
  • Price / book4.2× · lower than 35% of 1,245
  • FCF yield-7.1% · higher than 47% of 835
CompanyMarket capP/ENet marginRev. growth
Carlsmed, Inc.🇺🇸$420 M—-55.8%+86.0%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
UnitedHealth Group Incorporated🇺🇸$367.7 B23.1×3.5%+11.8%
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Thermo Fisher Scientific Inc.🇺🇸$253.8 B35.9×14.9%+3.9%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Carlsmed, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Carlsmed, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Carlsmed, Inc.? Suggest a correction